safety

Lebwohl MG, Koo JY, Armstrong AW, Strober BE, Yoon SH, Rawnsley NN, Goehring EL Jr, Jacobson AA. Brodalumab: Seven-Year US Pharmacovigilance Report. Dermatol Ther (Heidelb).[...]

By afschroeder • July 30, 2025

Papp KA, Armstrong AW, Koresawa T, Otake K, Hirata M, Kano A. Efficacy and safety of ME3183, an oral phosphodiesterase 4 inhibitor, in patients with[...]

By afschroeder • July 27, 2025

Saberi S, Abraham TP, Choudhury L, Barriales-Villa R, Elliott PM, Nassif ME, Oreziak A, Owens AT, Tower-Rader A, Rader F, Garcia-Pavia P, Olivotto I, Coats[...]

By afschroeder • June 21, 2025

Kim NH, Chin KM, McLaughlin VV, Ong R, MacDonald G, Martin N, Senatore A, Channick R. Macitentan and Tadalafil Combination Therapy in Patients with Pulmonary[...]

By sjmartinez • May 20, 2025

Lau G, Sangro B, Cheng AL, Kudo M, Kelley RK, Tak WY, Gasbarrini A, Reig M, Lim HY, Tougeron D, De Toni EN, Tam VC,[...]

By sjmartinez • May 19, 2025

Eichenfield LF, Stein Gold LF, Simpson EL, Zaenglein AL, Armstrong AW, Tollefson MM, Soong W, Lee LW, Devani AR, Forman SB, Siri DD, Kallender H,[...]

By sjmartinez • May 18, 2025

Merola JF, Ferris LK, Sobell JM, Sofen H, Osborne J, Vaile J, Jou YM, Daamen C, Scotto J, Scharnitz T, Lebwohl M. Deucravacitinib: Adverse Events[...]

By sjmartinez • February 8, 2025

Sofen HL, Gebauer K, Spelman L, Yamauchi PS, Yao SL, Nishandar T, Kopeloff I, Crane M, Gogineni R, Kothekar M, Bagel J. Efficacy and Safety[...]

By sjmartinez • December 26, 2024

Lebwohl MG, Koo JY, Armstrong AW, Strober BE, Yoon SH, Rawnsley NN, Goehring EL Jr, Mangin GD, Jacobson AA. Brodalumab: Six-Year US Pharmacovigilance Report. Dermatol[...]

By sjmartinez • November 27, 2024

Chin KM, Channick R, Kim NH, MacDonald G, Ong R, Martin N, Senatore A, McLaughlin VV. Macitentan and Tadalafil Combination Therapy in Incident and Prevalent[...]

By sjmartinez • September 25, 2024